Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more
Location: 225 Franklin Street, Boston, MA, 02110, United States | Website: https://ateapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
278.5M
52 Wk Range
$2.46 - $4.14
Previous Close
$3.51
Open
$3.51
Volume
360,220
Day Range
$3.46 - $3.56
Enterprise Value
-99.92M
Cash
379.7M
Avg Qtr Burn
-29.22M
Insider Ownership
12.72%
Institutional Own.
71.73%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C | Phase 3 Data readout | |
AT-527 (Bemnifosbuvir) Details COVID-19, Infectious disease | Failed Discontinued | |
AT-752 Details Infectious disease, Dengue Fever | Failed Discontinued | |
Failed Discontinued |